Tackling POTS Needs More Than Just a Sympathetic Approach.
Melanie Dani, Artur Fedorowski
https://pubmed.ncbi.nlm.nih.gov/39413203Actively Recruiting
Led by Mayo Clinic · Updated on 2026-03-05
50
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating pyridostigmine compared to a placebo for treating postural tachycardia syndrome POTS, a condition characterized by rapid heart rate and symptoms like weakness and lightheadedness when standing. This phase 2 study aims to see if pyridostigmine can improve heart rate and stabilize blood pressure in people with POTS. The study is double-blind and placebo-controlled, meaning neither participants nor doctors know who receives the active drug or placebo during the trial. Participants will be randomly assigned to one of two groups one taking 180 mg of time-release pyridostigmine daily, and the other taking a placebo capsule daily, both for 3 days. The study includes two visits to the outpatient General Clinical Research Center. The first visit lasts about 3 hours, and the second visit occurs 2 days later, lasting about 2 hours. During these visits, various tests and procedures assess autonomic and cardiovascular function. During each visit, participants will undergo a medical and neurological exam, height and weight measurement, and complete questionnaires about autonomic symptoms. Tests include an autonomic reflex screen with sweat gland response, cardiovascular recordings, the Valsalva maneuver, and a head-up tilt test. Blood samples will be taken to measure hormone levels while lying down and after standing. Researchers will measure changes in orthostatic symptoms using the Composite Autonomic Symptom Scale and monitor heart rate and plasma norepinephrine changes. Safety and response will be closely observed throughout the short study period.
CONDITIONS
A Study of Pyridostigmine in Postural Tachycardia Syndrome
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mayo Clinic
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Pyridostigmine (180 mg capsule daily) | Placebo (capsule daily) |
|---|---|---|
| What it is | An oral medication (pyridostigmine) given as a 180 mg capsule taken once daily. | A matching placebo capsule taken once daily, without active pyridostigmine. |
| Role in the trial | Assesses whether pyridostigmine reduces orthostatic symptoms in people with POTS. | Serves as an inactive comparator to help determine the effect of pyridostigmine. |
| Primary use | Investigational use for symptom control in postural tachycardia syndrome (POTS). | Contains no active medication; included to compare effect versus active drug. |
| How it is given or performed | Taken by mouth as a single capsule each day for 3 days. | Taken by mouth as a single capsule each day for 3 days, matching the active drug process. |
| Evidence status | Effectiveness and safety in POTS remain investigational; no published results from this trial are established. | Serves as a comparison group; by definition, contains no active medication. |
| Important limitations | The use of pyridostigmine in POTS is investigational. Duration of treatment and effect assessment is limited to 3 days and a small population size. Broader clinical benefit and long-term safety are not addressed in this trial. | Placebo use does not inform about effectiveness of current recommended therapies. Short assessment period means longer-term outcomes are not evaluated. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 days
Participants take one capsule per day of either pyridostigmine or placebo for 3 days while undergoing tests and assessments.
2 visits (in-person): Visit 1 lasts about 3 hours and Visit 2 occurs 2 days later and lasts about 2 hours
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Melanie Dani, Artur Fedorowski
https://pubmed.ncbi.nlm.nih.gov/39413203Mayo Clinic
Lead Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Collaborating Sponsor